Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
29 avr. 2024 07h59 HE
|
Pasithea
Pasithea Therapeutics' PAS-004 abstract accepted for ASCO poster presentation: novel MEK inhibitor shows promise for NF1 and cancer therapy.
Spexis Announces Changes to the Executive Committee
01 nov. 2023 02h20 HE
|
Spexis AG
Spexis Announces Changes to the Executive Committee
Spexis to host business update conference call on October 9, 2023
06 oct. 2023 01h30 HE
|
Spexis AG
Spexis to host business update conference call on October 9, 2023
Spexis provides business update and announces financial results for the first half of 2023
29 sept. 2023 01h30 HE
|
Spexis AG
Spexis provides business update and announces financial results for the first half of 2023
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
28 sept. 2023 01h30 HE
|
Spexis AG
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
15 août 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle...
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
30 juin 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and...
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains
07 juin 2023 01h15 HE
|
Spexis AG
ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...